Your browser doesn't support javascript.
loading
A predictive survival model for patients with head and neck squamous cell carcinoma treated with immune check point inhibitors.
Bonomi, M; Bhateja, P; Issa, M; Klamer, B; Pan, X; Blakaj, A; Karivedu, V; Mousa, L; Mitchell, D; Gamez, M; Kang, S; Seim, Nolan B; Old, M; Carrau, R; Rocco, J; Blakaj, D.
Afiliação
  • Bonomi M; Division of Medical Oncology, Ohio State University, Columbus, United States. Electronic address: marcelo.bonomi@osumc.edu.
  • Bhateja P; Division of Medical Oncology, Ohio State University, Columbus, United States.
  • Issa M; Division of Medical Oncology, Ohio State University, Columbus, United States.
  • Klamer B; Department of Biomedical Informatics, Ohio State University, Columbus, United States.
  • Pan X; Department of Biomedical Informatics, Ohio State University, Columbus, United States.
  • Blakaj A; Division of Radiation Oncology, Yale University, New Haven, United States.
  • Karivedu V; Division of Medical Oncology, Ohio State University, Columbus, United States.
  • Mousa L; Division of Medical Oncology, Ohio State University, Columbus, United States.
  • Mitchell D; Division of Radiation Oncology, Ohio State University, Columbus, United States.
  • Gamez M; Division of Radiation Oncology, Ohio State University, Columbus, United States.
  • Kang S; Division of Otolaryngology, Ohio State University, Columbus, United States.
  • Seim NB; Division of Otolaryngology, Ohio State University, Columbus, United States.
  • Old M; Division of Otolaryngology, Ohio State University, Columbus, United States.
  • Carrau R; Division of Otolaryngology, Ohio State University, Columbus, United States.
  • Rocco J; Division of Otolaryngology, Ohio State University, Columbus, United States.
  • Blakaj D; Division of Radiation Oncology, Ohio State University, Columbus, United States.
Oral Oncol ; 110: 104900, 2020 11.
Article em En | MEDLINE | ID: mdl-32702630
ABSTRACT

BACKGROUND:

ICIs have expanded treatment options for HNSCC. A minority of the patients respond to these expensive treatments. PATIENTS AND

METHODS:

This is a single institutional retrospective review on 121 unresectable or metastatic HNSCC patients treated with ICIs. We predicted that inflammatory markers available through routine blood work, in addition to clinical characteristics may divide patients into groups more or less likely to respond to these agents. Here we develop and internally validate our nomogram to predict survival in patients treated with ICIs.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Terapia de Alvo Molecular / Carcinoma de Células Escamosas de Cabeça e Pescoço / Inibidores de Checkpoint Imunológico Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Terapia de Alvo Molecular / Carcinoma de Células Escamosas de Cabeça e Pescoço / Inibidores de Checkpoint Imunológico Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article